论文部分内容阅读
目的探讨血浆骨桥蛋白与系统性红斑狼疮(SLE)活动程度的关系。方法采用ELISA方法检测28例健康人与38例SLE患者血浆骨桥蛋白水平,以分析其与SLE活动性变化关系。结果SLE患者血浆骨桥蛋白水平(420±203)ng/mL明显高于正常对照组(73±14)ng/mL,P＜0．001；SLE蛋白尿组(623±88)ng/mL明显高于非蛋白尿组(288±135)ng/mL,P＜0．001；活动组(529±143)ng/mL明显高于非活动组(185±66)ng/mL,P＜0．001；糖皮质激素治疗后血浆骨桥蛋白水平(142±22)ng/mL与治疗前水平(556±130)ng/mL相比,差异有统计学意义(P＜0．001)；关节炎组(489±153)ng/mL与非关节炎组(375±222)ng/mL之间差异无统计学意义,P＞0．05。血浆骨桥蛋白水平与SLE DAI呈正相关,r= 0．93,P＜0．001；与C3呈负相关,r=-0．49,P＜0．05；与ANA滴度、血细胞沉降率、C4水平无相关性(P＞0．05)。结论血浆骨桥蛋白水平变化与SLE活动程度、肾脏损害及疾病进展有关。
Objective To investigate the relationship between plasma osteopontin and systemic lupus erythematosus (SLE) activity. Methods ELISA method was used to detect the plasma osteopontin level in 28 healthy people and 38 SLE patients to analyze their relationship with the changes of SLE activity. Results The level of osteopontin (420 ± 203) ng / mL in SLE patients was significantly higher than that of controls (73 ± 14) ng / mL, P <0.001; SLE proteinuria patients (623 ± 88) ng / (288 ± 135) ng / mL, P <0.001; activity group (529 ± 143) ng / mL was significantly higher than that of inactive group (185 ± 66) ng / mL, P < 001; The level of plasma osteopontin (142 ± 22) ng / mL after glucocorticoid treatment was significantly lower than that before treatment (556 ± 130) ng / mL (P <0.001) There was no significant difference between the group (489 ± 153) ng / mL and the non-arthritis group (375 ± 222) ng / mL, P> 0.05. There was a positive correlation between plasma osteopontin level and SLE DAI, r = 0.93, P <0.001; negatively correlated with C3, r = -0.49, P <0.05; , C4 level no correlation (P> 0.05). Conclusion The change of plasma osteopontin level is related to the degree of SLE activity, renal damage and disease progression.